Oxaliplatin

This classification denotes a platinum compound with the molecular formula C8H14N2O4Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04ZR38536J, chemically known as (sp-4-3-(cis))-(1,2-cyclohexanediamine-n,n)(ethanedioato(2-)-o,o)platinum but more generally known as oxaliplatin, which bears US NIH Compound Identifier 77994. European Medicines Agency schedules Oxaliplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09490MIG. The term OXALIPLATIN is an International Non-Proprietary Name. World Health Organization schedules oxaliplatin in its Anatomical Therapeutic Chemical (ATC) Classification. OXALIPLATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule oxaliplatin under HS 28439090 and SITC 52432. As of Q4 2014, OXALIPLATIN remains US FDA's Preferred Term for this commodity. Oxaliplatin bears US NLM identifiers UMLS ID C0069717 and NCI Concept Code C1181. SMILES: [PT].OC(=O)C(=O)O.NC1C(N)CCCC1.